# Raymond F Schinazi

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 321 papers | 10,778 citations | 56 h-index | 91 g-index |
| 336 ext. papers | 12,296 ext. citations | 6.4 avg, IF | 6.35 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 321 | Elimination of Aicardi Goutières Syndrome Protein SAMHD1 Activates Cellular Innate Immunity and Suppresses SARS-CoV-2 Replication.. *Journal of Biological Chemistry*, **2022**, 101635 | 5.4 | 0 |
| 320 | Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies.. *ImmunoHorizons*, **2022**, 6, 144-155 | 2.7 | 0 |
| 319 | Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern.. *IScience*, **2022**, 103968 | 6.1 | 0 |
| 318 | Diastereoselective Synthesis of 2′-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication.. *ACS Omega*, **2022**, 7, 1452-1461 | 3.9 | 0 |
| 317 | The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.. *Antiviral Therapy*, **2022**, 27, 13596535211067599 | 1.6 | 0 |
| 316 | Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines. *Molecular Diversity*, **2021**, 25, 2045-2052 | 3.1 | 0 |
| 315 | TREM2+ and interstitial macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques **2021**, | | 2 |
| 314 | Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses. *Journal of Natural Products*, **2021**, 84, 3001-3007 | 4.9 | 1 |
| 313 | Reply to Jorgensen, et al. *Clinical Infectious Diseases*, **2021**, 73, e3978-e3979 | 11.6 | |
| 312 | Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al. *Clinical Infectious Diseases*, **2021**, 73, e3980-e3981 | 11.6 | 0 |
| 311 | Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. *Clinical Infectious Diseases* , **2021**, | 11.6 | 11 |
| 310 | Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. *Microorganisms*, **2021**, 9, | 4.9 | 27 |
| 309 | -N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *Journal of Infectious Diseases*, **2021**, 224, 415-419 | 7 | 65 |
| 308 | Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. *Metabolism Open*, **2021**, 10, 100090 | 2.8 | 8 |
| 307 | Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. *Clinical Infectious Diseases*, **2021**, 72, 1247-1250 | 11.6 | 72 |
| 306 | Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. *Cell*, **2021**, 184, 460-475.e21 | 56.2 | 84 |
| 305 | COVID-19: Discovery, diagnostics and drug development. *Journal of Hepatology*, **2021**, 74, 168-184 | 13.4 | 133 |

| | | | |
|---|---|---|---|
| 304 | Covid-19 will not "magically disappear": Why access to widespread testing is paramount. *American Journal of Hematology*, **2021**, 96, 174-178 | 7.1 | 3 |
| 303 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. *Bioorganic and Medicinal Chemistry*, **2021**, 31, 115952 | 3.4 | 0 |
| 302 | Moving Fast Toward Hepatitis B Virus Elimination. *Advances in Experimental Medicine and Biology*, **2021**, 1322, 115-138 | 3.6 | 0 |
| 301 | Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator. *Viruses*, **2021**, 13, | 6.2 | 2 |
| 300 | Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. *Current Research in Pharmacology and Drug Discovery*, **2021**, 2, 100045 | 3 | 4 |
| 299 | Disproportionate presence of adenosine in mitochondrial and chloroplast DNA of. *IScience*, **2021**, 24, 102005 | 6.1 | 2 |
| 298 | Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. *Journal of Clinical Pharmacology*, **2021**, 61, 1555-1566 | 2.9 | 0 |
| 297 | Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. *Journal of Biological Chemistry*, **2021**, 297, 100770 | 5.4 | 62 |
| 296 | Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 Mutations Associated with Variants of Concern. *Journal of Clinical Microbiology*, **2021**, 59, e0144621 | 9.7 | 8 |
| 295 | The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency. *Frontiers in Immunology*, **2021**, 12, 720697 | 8.4 | 4 |
| 294 | Structural and functional characterization explains loss of dNTPase activity of the cancer-specific R366C/H mutant SAMHD1 proteins. *Journal of Biological Chemistry*, **2021**, 297, 101170 | 5.4 | 1 |
| 293 | RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests.. *IEEE Open Journal of Engineering in Medicine and Biology*, **2021**, 2, 286-290 | 5.9 | 1 |
| 292 | Ribonucleotide incorporation in yeast genomic DNA shows preference for cytosine and guanosine preceded by deoxyadenosine. *Nature Communications*, **2020**, 11, 2447 | 17.4 | 12 |
| 291 | 7-Deaza-7-fluoro-2C-methyladenosine inhibits Zika virus infection and viral-induced neuroinflammation. *Antiviral Research*, **2020**, 180, 104855 | 10.8 | 3 |
| 290 | Synthesis of 4Substituted-2Deoxy-2Fluoro Nucleoside Analogs as Potential Antiviral Agents. *Molecules*, **2020**, 25, | 4.8 | 2 |
| 289 | Viral protein X reduces the incorporation of mutagenic noncanonical rNTPs during lentivirus reverse transcription in macrophages. *Journal of Biological Chemistry*, **2020**, 295, 657-666 | 5.4 | 1 |
| 288 | Potent in vitro activity of D-4chloromethyl-2deoxy-2fluorocytidine against Nipah virus. *Antiviral Research*, **2020**, 175, 104712 | 10.8 | 4 |
| 287 | Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. *EMBO Molecular Medicine*, **2020**, 12, e10419 | 12 | 14 |

| | | | |
|---|---|---|---|
| 286 | SAMHD1 Functions and Human Diseases. *Viruses*, **2020**, 12, | 6.2 | 13 |
| 285 | Nucleoside Antiviral Agents for HCV **2020**, 906-914 | | |
| 284 | Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques **2020**, | | 3 |
| 283 | Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy. *Journal of Viral Hepatitis*, **2020**, 27, 261-269 | 3.4 | 2 |
| 282 | Intracellular metabolism and potential cardiotoxicity of a D-2O-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication. *Nucleosides, Nucleotides and Nucleic Acids*, **2020**, 39, 204-224 | 1.4 | 2 |
| 281 | Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses and in Humanized Mice. *Antimicrobial Agents and Chemotherapy*, **2020**, 64, | 5.9 | 12 |
| 280 | Enhanced enzyme kinetics of reverse transcriptase variants cloned from animals infected with SIVmac239 lacking viral protein X. *Journal of Biological Chemistry*, **2020**, 295, 16975-16986 | 5.4 | 1 |
| 279 | Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery. *Journal of Biological Chemistry*, **2020**, 295, 13432-13443 | 5.4 | 3 |
| 278 | Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase. *Journal of Chemical Information and Modeling*, **2020**, 60, 6566-6578 | 6.1 | 1 |
| 277 | Repurposing Nucleoside Analogs for Human Coronaviruses. *Antimicrobial Agents and Chemotherapy* , **2020**, 65, | 5.9 | 28 |
| 276 | Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. *Molecules*, **2020**, 25, | 4.8 | 1 |
| 275 | Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model. *Journal of NeuroVirology*, **2020**, 26, 838-845 | 3.9 | |
| 274 | Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs. *Nucleosides, Nucleotides and Nucleic Acids*, **2020**, 39, 671-687 | 1.4 | 1 |
| 273 | Novel 1Chomo--2Cdeoxy-nucleosides: synthesis, characterization and biological activity. *RSC Advances*, **2020**, 10, 15815-15824 | 3.7 | 2 |
| 272 | Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. *Journal of Neuroinflammation*, **2019**, 16, 182 | 10.1 | 20 |
| 271 | Discovery of a Series of 2C-Fluoro,2C-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. *Journal of Medicinal Chemistry*, **2019**, 62, 1859-1874 | 8.3 | 6 |
| 270 | Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. *International Journal of Infectious Diseases*, **2019**, 83, 98-101 | 10.5 | 11 |
| 269 | Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses. *Antimicrobial Agents and Chemotherapy*, **2019**, 63, | 5.9 | 6 |

| | | | |
|---|---|---|---|
| 268 | Synthesis of 2-fluoro-substituted and 2,6-modified purine 2′,3′-dideoxy-2′,3′-difluoro-d-arabinofuranosyl nucleosides from d-xylose. *Tetrahedron*, **2019**, 75, 2037-2046 | 2.4 | 3 |
| 267 | Efficient pre-catalytic conformational change of reverse transcriptases from SAMHD1 non-counteracting primate lentiviruses during dNTP incorporation. *Virology*, **2019**, 537, 36-44 | 3.6 | 5 |
| 266 | Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. *Protein Science*, **2019**, 28, 1664-1675 | 6.3 | 13 |
| 265 | Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus. *Antimicrobial Agents and Chemotherapy*, **2019**, 63, | 5.9 | 5 |
| 264 | Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 126639 | 2.9 | 4 |
| 263 | FRI-157-Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation. *Journal of Hepatology*, **2019**, 70, e457 | 13.4 | 3 |
| 262 | Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages. *Retrovirology*, **2019**, 16, 29 | 3.6 | 2 |
| 261 | Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study. *Antiviral Therapy*, **2019**, 24, 567-579 | 1.6 | 2 |
| 260 | Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. *Viruses*, **2019**, 11, | 6.2 | 5 |
| 259 | Structural and Antiviral Studies of the Human Norovirus GII.4 Protease. *Biochemistry*, **2019**, 58, 900-907 | 3.2 | 7 |
| 258 | Synthesis and anti-HCV activity of β-d-2′-deoxy-2′-α-chloro-2′-β-fluoro and β-d-2′-deoxy-2′-α-bromo-2′-β-fluoro nucleosides and their phosphoramidate prodrugs. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 664-676 | 3.4 | 2 |
| 257 | Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients. *Antiviral Therapy*, **2019**, 24, 177-186 | 1.6 | 2 |
| 256 | Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP). *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2018**, 78, 34-42 | 3.1 | 13 |
| 255 | Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient. *Hepatology*, **2018**, 67, 2051-2054 | 11.2 | 3 |
| 254 | Towards HBV curative therapies. *Liver International*, **2018**, 38 Suppl 1, 102-114 | 7.9 | 44 |
| 253 | Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. *Liver International*, **2018**, 38 Suppl 1, 7-13 | 7.9 | 91 |
| 252 | A research agenda for curing chronic hepatitis B virus infection. *Hepatology*, **2018**, 67, 1127-1131 | 11.2 | 51 |
| 251 | Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques. *Journal of Virology*, **2018**, 92, | 6.6 | 34 |

| | | | |
|---|---|---|---|
| 250 | Template-assisted synthesis of adenine-mutagenized cDNA by a retroelement protein complex. *Nucleic Acids Research*, **2018**, 46, 9711-9725 | 20.1 | 16 |
| 249 | Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2165-2170 | 2.9 | 6 |
| 248 | Expression, Purification and Characterization of a GII.4 Norovirus Protease from Minerva Virus. *Infectious Disorders - Drug Targets*, **2018**, 18, 224-232 | 1.1 | 1 |
| 247 | SAMHD1-Mediated Negative Regulation of Cellular dNTP Levels: HIV-1, Innate Immunity, and Cancers **2018**, 313-325 | | 1 |
| 246 | Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages. *Retrovirology*, **2018**, 15, 69 | 3.6 | 5 |
| 245 | Interplay of ancestral non-primate lentiviruses with the virus-restricting SAMHD1 proteins of their hosts. *Journal of Biological Chemistry*, **2018**, 293, 16402-16412 | 5.4 | 15 |
| 244 | HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability. *Aids*, **2018**, 32, 1613-1623 | 3.5 | 5 |
| 243 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 904-910 | 2.9 | 8 |
| 242 | Characterization of Ed--Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 47 |
| 241 | Synthesis and antiviral evaluation of 2Q2Q3Q3Qtetrafluoro nucleoside analogs. *Tetrahedron Letters*, **2017**, 58, 642-644 | 2 | 7 |
| 240 | From HCV To HBV Cure. *Liver International*, **2017**, 37 Suppl 1, 73-80 | 7.9 | 24 |
| 239 | Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. *Antiviral Research*, **2017**, 144, 223-246 | 10.8 | 77 |
| 238 | 2QChloro,2Qfluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. *Journal of Medicinal Chemistry*, **2017**, 60, 5424-5437 | 8.3 | 16 |
| 237 | Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 5 |
| 236 | Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. *Biochemical and Biophysical Research Communications*, **2017**, 492, 668-673 | 3.4 | 20 |
| 235 | Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 21 |
| 234 | Synthesis and anti-HCV activity of a series of Ed-2Qdeoxy-2Qdibromo nucleosides and their corresponding phosphoramidate prodrugs. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 5296-5299 | 2.9 | 7 |
| 233 | Substrates and Inhibitors of SAMHD1. *PLoS ONE*, **2017**, 12, e0169052 | 3.7 | 32 |

| | | | |
|---|---|---|---|
| 232 | Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. *PLoS Pathogens*, **2017**, 13, e1006740 | 7.6 | 51 |
| 231 | Synthesis of (2S)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic Fluorination. *Journal of Organic Chemistry*, **2017**, 82, 13171-13178 | 4.2 | 5 |
| 230 | A CRISPR/Cas9 approach reveals that the polymerase activity of DNA polymerase is dispensable for HIV-1 infection in dividing and nondividing cells. *Journal of Biological Chemistry*, **2017**, 292, 14016-14025 | 5.4 | 8 |
| 229 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. *European Journal of Medicinal Chemistry*, **2017**, 138, 407-421 | 6.8 | 28 |
| 228 | Anti-human immunodeficiency activity of novel 2-arylpyrrolidine analogs. *Medicinal Chemistry Research*, **2017**, 26, 101-108 | 2.2 | 3 |
| 227 | Synthesis and antiviral evaluation of fluorinated acyclo-nucleosides and their phosphoramidates. *Nucleosides, Nucleotides and Nucleic Acids*, **2017**, 36, 66-82 | 1.4 | 1 |
| 226 | Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. *Oncotarget*, **2017**, 8, 94040-94053 | 3.3 | 5 |
| 225 | Jak Inhibitors Modulate Production of Replication-Competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells. *Pathogens and Immunity*, **2017**, 2, 199-218 | 4.9 | 16 |
| 224 | Metabolism of Nucleosides and Nucleotides Prodrugs. *Current Pharmaceutical Design*, **2017**, | 3.3 | 3 |
| 223 | Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. *Chemical Reviews*, **2016**, 116, 14379-14455 | 68.1 | 167 |
| 222 | Sonication-Assisted Synthesis of (E)-2-Methyl-but-2-enyl Nucleoside Phosphonate Prodrugs. *ChemistrySelect*, **2016**, 1, 3108-3113 | 1.8 | 7 |
| 221 | Modifications of Nucleosides, Nucleotides, and Nucleic Acids using Huisgen© [3+2] Azide–Alkyne Cycloaddition: Opening Pandora© Box **2016**, 309-336 | | |
| 220 | Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4101-5 | 2.9 | 13 |
| 219 | Synthesis and Evaluation of 2,6-Modified Purine 2′-C-Methyl Ribonucleosides as Inhibitors of HCV Replication. *ACS Medicinal Chemistry Letters*, **2016**, 7, 17-22 | 4.3 | 13 |
| 218 | Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages. *Virology*, **2016**, 491, 106-14 | 3.6 | 22 |
| 217 | A new oxygen modification cyclooctaoxygen binds to nucleic acids as sodium crown complex. *Biochimica Et Biophysica Acta - General Subjects*, **2016**, 1860, 785-94 | 4 | |
| 216 | The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. *Neurobiology of Disease*, **2016**, 92, 137-43 | 7.5 | 40 |
| 215 | HIV latency reversal research and the potential effects on the central nervous system: is concern warranted?. *Journal of the International AIDS Society*, **2016**, 19, 21008 | 5.4 | |

| | | | |
|---|---|---|---|
| 214 | Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4659-69 | 5.9 | 10 |
| 213 | Zika Virus Infects Human Placental Macrophages. *Cell Host and Microbe*, **2016**, 20, 83-90 | 23.4 | 315 |
| 212 | SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. *Virology*, **2016**, 495, 92-100 | 3.6 | 56 |
| 211 | Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. *Clinics in Liver Disease*, **2016**, 20, 737-749 | 4.6 | 23 |
| 210 | Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. *The Lancet Gastroenterology and Hepatology*, **2016**, 1, 97-104 | 18.8 | 65 |
| 209 | Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3711-5 | 2.9 | 1 |
| 208 | Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 8596-601 | 11.5 | 25 |
| 207 | D-2C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5Triphosphate Forms. *Journal of Medicinal Chemistry*, **2015**, 58, 3445-58 | 8.3 | 26 |
| 206 | Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors. *Journal of Molecular Modeling*, **2015**, 21, 282 | 2 | 5 |
| 205 | Synthesis and antiviral evaluation of 2,3dideoxy-2,3difluoro-D-arabinofuranosyl 2,6-disubstituted purine nucleosides. *Heterocyclic Communications*, **2015**, 21, 315-327 | 1.7 | 5 |
| 204 | Role of Marine Natural Products in the Genesis of Antiviral Agents. *Chemical Reviews*, **2015**, 115, 9655-706 | 68.1 | 62 |
| 203 | Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells. *Virology*, **2015**, 485, 313-21 | 3.6 | 5 |
| 202 | Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. *Future Microbiology*, **2015**, 10, 1773-82 | 2.9 | 27 |
| 201 | Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor **2015**, 61-80 | | 4 |
| 200 | Predicting Zika virus structural biology: Challenges and opportunities for intervention. *Antiviral Chemistry and Chemotherapy*, **2015**, 24, 118-26 | 3.5 | 42 |
| 199 | Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis. *Oncotarget*, **2015**, 6, 11047-60 | 3.3 | 20 |
| 198 | Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template. *Antiviral Research*, **2015**, 115, 75-82 | 10.8 | 4 |
| 197 | Mechanistic and Kinetic Differences between Reverse Transcriptases of Vpx Coding and Non-coding Lentiviruses. *Journal of Biological Chemistry*, **2015**, 290, 30078-86 | 5.4 | 23 |

| | | | |
|---|---|---|---|
| 196 | Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. *Virology*, **2015**, 476, 196-205 | 3.6 | 168 |
| 195 | Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. *Gut*, **2015**, 64, 1314-26 | 19.2 | 198 |
| 194 | Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases. *Tetrahedron Letters*, **2015**, 56, 3587-3590 | 2 | 5 |
| 193 | Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. *Hepatology*, **2014**, 60, 37-45 | 11.2 | 88 |
| 192 | Molecular mechanism of HIV-1 resistance to 3′-azido-2′,3′-dideoxyguanosine. *Antiviral Research*, **2014**, 101, 62-7 | 10.8 | 3 |
| 191 | Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 1977-86 | 5.9 | 59 |
| 190 | Chutes and ladders in hepatitis C nucleoside drug development. *Antiviral Research*, **2014**, 102, 119-47 | 10.8 | 60 |
| 189 | Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 6665-6671 | 3.4 | 5 |
| 188 | Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. *Journal of Medicinal Chemistry*, **2014**, 57, 10031-43 | 8.3 | 38 |
| 187 | Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3927-33 | 5.9 | 9 |
| 186 | Synthesis of nucleoside phosphate and phosphonate prodrugs. *Chemical Reviews*, **2014**, 114, 9154-218 | 68.1 | 332 |
| 185 | Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4014-9 | 5.9 | 8 |
| 184 | Approaches to hepatitis C treatment and cure using NS5A inhibitors. *Infection and Drug Resistance*, **2014**, 7, 41-56 | 4.2 | 45 |
| 183 | Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV. *PLoS ONE*, **2014**, 9, e86997 | 3.7 | 2 |
| 182 | Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART. *PLoS ONE*, **2014**, 9, e87914 | 3.7 | 15 |
| 181 | Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution. *PLoS ONE*, **2014**, 9, e88258 | 3.7 | 9 |
| 180 | Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses. *Retrovirology*, **2014**, 11, 111 | 3.6 | 18 |
| 179 | dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages. *Retrovirology*, **2014**, 11, 63 | 3.6 | 29 |

| | | | |
|---|---|---|---|
| 178 | HCV direct-acting antiviral agents: the best interferon-free combinations. *Liver International*, **2014**, 34 Suppl 1, 69-78 | 7.9 | 186 |
| 177 | Anti-HIV-1 screening of (2E)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl)prop-2-en-1-ones. *Medicinal Chemistry Research*, **2014**, 23, 402-407 | 2.2 | 7 |
| 176 | Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6325-30 | 2.9 | 14 |
| 175 | Treatment as prevention and cure towards global eradication of hepatitis C virus. *Trends in Microbiology*, **2013**, 21, 625-33 | 12.4 | 52 |
| 174 | Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach. *Journal of Organic Chemistry*, **2013**, 78, 723-7 | 4.2 | 4 |
| 173 | Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3385-8 | 2.9 | 7 |
| 172 | Best strategies for global HCV eradication. *Liver International*, **2013**, 33 Suppl 1, 68-79 | 7.9 | 73 |
| 171 | Synthesis and evaluation of non-dimeric HCV NS5A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 2031-4 | 2.9 | 18 |
| 170 | Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1262-9 | 5.9 | 28 |
| 169 | Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors. *Current Opinion in HIV and AIDS*, **2013**, 8, 556-64 | 4.2 | 7 |
| 168 | Significance of endangered and threatened plant natural products in the control of human disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 16832-7 | 11.5 | 53 |
| 167 | Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5344-54 | 5.9 | 86 |
| 166 | Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3488-91 | 2.9 | 21 |
| 165 | Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 6186-91 | 5.9 | 9 |
| 164 | Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. *Drug Discovery Today: Technologies*, **2012**, 9, e183-e193 | 7.1 | 11 |
| 163 | Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives. *Medicinal Chemistry Research*, **2012**, 21, 3741-3749 | 2.2 | 43 |
| 162 | Scaleable processes for the synthesis of (-)-ĐD-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-ĐD-2-aminopurine dioxolane (APD). *Tetrahedron*, **2012**, 68, 5738-5743 | 2.4 | 6 |
| 161 | Synthesis and evaluation of novel potent HCV NS5A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4864-8 | 2.9 | 13 |

| | | | |
|---|---|---|---|
| 160 | The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. *Molecular Biology International*, **2012**, 2012, 625983 | | 20 |
| 159 | Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase. *Molecular Pharmacology*, **2012**, 82, 125-33 | 4.3 | 14 |
| 158 | Antiviral activity of nucleoside analogues against norovirus. *Antiviral Therapy*, **2012**, 17, 981-91 | 1.6 | 51 |
| 157 | Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. *Antiviral Therapy*, **2012**, 17, 1233-42 | 1.6 | 55 |
| 156 | Simian immunodeficiency virus macaque models of HIV latency. *Current Opinion in HIV and AIDS*, **2011**, 6, 57-61 | 4.2 | 17 |
| 155 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3′-azido-2′,3′-dideoxypurine nucleosides. *European Journal of Medicinal Chemistry*, **2011**, 46, 3832-44 | 6.8 | 9 |
| 154 | In silico study supports the efficacy of a reduced dose regimen for stavudine. *Antiviral Research*, **2011**, 92, 372-7 | 10.8 | 5 |
| 153 | Synthesis of purine modified 2′-C-methyl nucleosides as potential anti-HCV agents. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6788-92 | 2.9 | 11 |
| 152 | Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5′-triphosphates. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 7094-8 | 2.9 | 18 |
| 151 | Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection. *Tetrahedron*, **2011**, 67, 5487-5493 | 2.4 | 19 |
| 150 | Synthesis and Biological Evaluation of 4′,3′-Propylene-Linked Bicyclic Nucleosides. *European Journal of Organic Chemistry*, **2011**, 2011, 7390-7399 | 3.2 | 7 |
| 149 | The base component of 3′-azido-2′,3′-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3758-64 | 5.9 | 1 |
| 148 | Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 2054-60 | 5.9 | 7 |
| 147 | Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1248-55 | 5.9 | 6 |
| 146 | Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. *Journal of Biological Chemistry*, **2010**, 285, 39380-91 | 5.4 | 82 |
| 145 | Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. *Journal of Virology*, **2010**, 84, 2913-22 | 6.6 | 129 |
| 144 | Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry. *Analytical Chemistry*, **2010**, 82, 1982-9 | 7.8 | 40 |
| 143 | Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. *Antiviral Therapy*, **2010**, 15, 185-92 | 1.6 | 11 |

| | | | |
|---|---|---|---|
| 142 | Advances in nucleoside monophosphate prodrugs as anti-HCV agents. *Antiviral Therapy*, **2010**, 15, 935-50 | 1.6 | 49 |
| 141 | Synthesis of 6-imino-5-tetrahydro-1H-2-pyrrolylidenhexahydro-2,4-pyrimidinediones as intermediates for the synthesis of C-azanucleosides. *Tetrahedron Letters*, **2010**, 51, 231-233 | 2 | 7 |
| 140 | Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 60-4 | 2.9 | 11 |
| 139 | Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. *PLoS ONE*, **2010**, 5, e9948 | 3.7 | 40 |
| 138 | Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. *PLoS ONE*, **2010**, 5, e11640 | 3.7 | 12 |
| 137 | Antiretroviral therapy in macrophages: implication for HIV eradication. *Antiviral Chemistry and Chemotherapy*, **2009**, 20, 63-78 | 3.5 | 75 |
| 136 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3′-azido-2′,3′-dideoxypurine nucleosides. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 3715-9 | 5.9 | 16 |
| 135 | Anti-hepatitis C virus activity of novel beta-d-2′-C-methyl-4′-azido pyrimidine nucleoside phosphoramidate prodrugs. *Antiviral Chemistry and Chemotherapy*, **2009**, 20, 99-106 | 3.5 | 23 |
| 134 | Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. *Antiviral Research*, **2009**, 83, 317-23 | 10.8 | 12 |
| 133 | Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases. *European Journal of Medicinal Chemistry*, **2009**, 44, 3845-51 | 6.8 | 8 |
| 132 | Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry. *Chemical Reviews*, **2009**, 109, 4207-20 | 68.1 | 670 |
| 131 | Approaches for the development of antiviral compounds: the case of hepatitis C virus. *Handbook of Experimental Pharmacology*, **2009**, 25-51 | 3.2 | 8 |
| 130 | Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. *Cell Host and Microbe*, **2008**, 4, 260-270 | 23.4 | 102 |
| 129 | Combinations of 2′-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. *Antiviral Chemistry and Chemotherapy*, **2008**, 19, 25-31 | 3.5 | 30 |
| 128 | Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4241-50 | 5.9 | 13 |
| 127 | Synthesis and anti-HIV activity of 5-haloethynyl and 5-(1,2-dihalo)vinyl analogues of AZT and FLT. *Tetrahedron*, **2008**, 64, 4444-4452 | 2.4 | 8 |
| 126 | Preparation of ribavirin analogues by copper- and ruthenium-catalyzed azide-alkyne 1,3-dipolar cycloaddition. *Tetrahedron*, **2008**, 64, 9044-9051 | 2.4 | 69 |
| 125 | Pharmacokinetics of the antiviral agent beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine in rhesus monkeys. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2877-82 | 5.9 | 10 |

| | | | |
|---|---|---|---|
| 124 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 4428-31 | 2.9 | 56 |
| 123 | Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. *Antiviral Research*, **2007**, 75, 198-209 | 10.8 | 16 |
| 122 | Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 503-9 | 5.9 | 92 |
| 121 | Development of a novel mouse model to evaluate drug candidates against hepatitis B virus. *Antiviral Chemistry and Chemotherapy*, **2007**, 18, 213-23 | 3.5 | 9 |
| 120 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2130-5 | 5.9 | 10 |
| 119 | Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2078-84 | 5.9 | 13 |
| 118 | Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. *Antiviral Chemistry and Chemotherapy*, **2007**, 18, 329-41 | 3.5 | 9 |
| 117 | Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. *Antiviral Research*, **2006**, 71, 322-34 | 10.8 | 49 |
| 116 | Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. *Antiviral Chemistry and Chemotherapy*, **2006**, 17, 79-87 | 3.5 | 97 |
| 115 | Facile purification of honokiol and its antiviral and cytotoxic properties. *Journal of Medicinal Chemistry*, **2006**, 49, 3426-7 | 8.3 | 47 |
| 114 | Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1712-5 | 2.9 | 55 |
| 113 | The boron-neutron capture agent beta-D-5-o-carboranyl-2′-deoxyuridine accumulates preferentially in dividing brain tumor cells. *Journal of Neuro-Oncology*, **2005**, 74, 275-80 | 4.8 | 7 |
| 112 | Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. *Journal of Medicinal Chemistry*, **2005**, 48, 3949-52 | 8.3 | 22 |
| 111 | ESR as a valuable tool for the investigation of the dynamics of EPC and EPC/cholesterol liposomes containing a carboranyl-nucleoside intended for BNCT. *Biochimica Et Biophysica Acta - Biomembranes*, **2005**, 1712, 81-91 | 3.8 | 11 |
| 110 | Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2′,3′-didehydro-2′,3′-dideoxy-2′-fluorocarbocyclic nucleosides. *Journal of Medicinal Chemistry*, **2005**, 48, 3736-48 | 8.3 | 30 |
| 109 | Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. *Journal of Medicinal Chemistry*, **2005**, 48, 5504-8 | 8.3 | 176 |
| 108 | In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1139-44 | 5.9 | 59 |
| 107 | In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 3930-2 | 5.9 | 16 |

| | | | |
|---|---|---|---|
| 106 | Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. *Antiviral Chemistry and Chemotherapy*, **2005**, 16, 117-27 | 3.5 | 13 |
| 105 | Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 2618-24 | 5.9 | 11 |
| 104 | The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. *Journal of Biological Chemistry*, **2005**, 280, 29047-52 | 5.4 | 36 |
| 103 | Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. *Journal of Virology*, **2005**, 79, 7349-54 | 6.6 | 54 |
| 102 | N4-hydroxycytosine dioxolane nucleosides and their activity against hepatitis B virus. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 1209-14 | 1.4 | 1 |
| 101 | Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 2589-97 | 5.9 | 7 |
| 100 | Synthesis of beta-enantiomers of N4-hydroxy-3'-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture. *Antiviral Chemistry and Chemotherapy*, **2004**, 15, 43-55 | 3.5 | 14 |
| 99 | Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1300-6 | 5.9 | 66 |
| 98 | Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 4636-42 | 5.9 | 23 |
| 97 | Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. *Current Topics in Medicinal Chemistry*, **2004**, 4, 895-919 | 3 | 65 |
| 96 | Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 3483-90 | 5.9 | 36 |
| 95 | Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. *Antiviral Research*, **2004**, 62, 57-64 | 10.8 | 14 |
| 94 | 2(1),3(1)-didehydro-2(1),3(1)-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 2159-62 | 2.9 | 4 |
| 93 | Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents. *Journal of Medicinal Chemistry*, **2004**, 47, 3399-408 | 8.3 | 50 |
| 92 | Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. *Nucleosides, Nucleotides and Nucleic Acids*, **2004**, 23, 291-306 | 1.4 | 12 |
| 91 | Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target. *Current Medicinal Chemistry*, **2004**, 11, 887-900 | 4.3 | 56 |
| 90 | Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose. *Antiviral Therapy*, **2004**, 9, 529-36 | 1.6 | 5 |
| 89 | Potent Antiviral Effect of Reverset in HIV-1-Infected Adults following a Single Oral Dose. *Antiviral Therapy*, **2004**, 9, 529-536 | 1.6 | 6 |

| | | | |
|---|---|---|---|
| 88 | Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine **2003**, 451-484 | | 1 |
| 87 | Emtricitabine. *Drugs*, **2003**, 63, 2425-2426 | 12.1 | 2 |
| 86 | l-2′,3′-Didehydro-2′,3′-dideoxy-3′-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. *Journal of Medicinal Chemistry*, **2003**, 46, 3245-56 | 8.3 | 43 |
| 85 | Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. *Antiviral Chemistry and Chemotherapy*, **2003**, 14, 115-25 | 3.5 | 21 |
| 84 | N4-acyl-modified D-2′,3′-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity. *Antiviral Chemistry and Chemotherapy*, **2003**, 14, 81-90 | 3.5 | 3 |
| 83 | Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. *Antiviral Chemistry and Chemotherapy*, **2003**, 14, 39-47 | 3.5 | 12 |
| 82 | Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 244-54 | 5.9 | 150 |
| 81 | HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset). *Antiviral Chemistry and Chemotherapy*, **2003**, 14, 49-59 | 3.5 | 29 |
| 80 | Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. *Journal of Virology*, **2003**, 77, 10689-94 | 6.6 | 67 |
| 79 | CD81 receptor expression in human cells: Implications for HCV therapeutics **2003**, 485-492 | | |
| 78 | Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. *Antiviral Research*, **2002**, 55, 141-50 | 10.8 | 22 |
| 77 | Interactions of enantiomers of 2′,3′-didehydro-2′,3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. *Antiviral Research*, **2002**, 56, 189-205 | 10.8 | 21 |
| 76 | Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. *Antiviral Research*, **2002**, 56, 115-27 | 10.8 | 13 |
| 75 | Viral pharmacodynamic model for (-)-beta-2′,3′-dideoxy-5-fluoro-3′-thiacytidine (emtricitabine) in chronically infected woodchucks. *Antiviral Chemistry and Chemotherapy*, **2002**, 13, 165-76 | 3.5 | 2 |
| 74 | Hepatitis B virus resistance to lamivudine and its clinical implications. *Antiviral Chemistry and Chemotherapy*, **2002**, 13, 143-55 | 3.5 | 9 |
| 73 | Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 3854-60 | 5.9 | 116 |
| 72 | DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1394-401 | 5.9 | 47 |
| 71 | Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. *Hepatology*, **2001**, 33, 751-7 | 11.2 | 313 |

| | | | |
|---|---|---|---|
| 70 | Antiviral L-nucleosides specific for hepatitis B virus infection. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 229-35 | 5.9 | 163 |
| 69 | Anti-HBV specific beta-L-2′-deoxynucleosides. *Nucleosides, Nucleotides and Nucleic Acids*, **2001**, 20, 597-607 | 1.4 | 20 |
| 68 | Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 158-65 | 5.9 | 78 |
| 67 | Synthesis and potent anti-HIV activity of L-3′-fluoro-2′,3′-unsaturated cytidine. *Organic Letters*, **2001**, 3, 4177-80 | 6.2 | 26 |
| 66 | The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. *Journal of Clinical Investigation*, **2001**, 107, 449-55 | 15.9 | 223 |
| 65 | Synthesis of 2′,3′-dideoxy-3′-fluoro-L-ribonucleosides as potential antiviral agents from D-sorbitol. *Carbohydrate Research*, **2000**, 328, 49-59 | 2.9 | 22 |
| 64 | Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. *Cancer Chemotherapy and Pharmacology*, **2000**, 46, 235-40 | 3.5 | 6 |
| 63 | Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 3465-72 | 5.9 | 100 |
| 62 | Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. *Journal of Virology*, **2000**, 74, 684-92 | 6.6 | 70 |
| 61 | In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 1783-8 | 5.9 | 89 |
| 60 | Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy. *Cancer Chemotherapy and Pharmacology*, **2000**, 45, 351-61 | 3.5 | 11 |
| 59 | Cellular pharmacology of the D- and L-enantiomers of beta-5-o-carboranyl-2′-deoxyuridine. *Nucleosides, Nucleotides and Nucleic Acids*, **2000**, 19, 691-702 | 1.4 | 13 |
| 58 | Synthesis and antiviral activities of enantiomeric 1-[2-(hydroxymethyl) cyclopropyl] methyl nucleosides. *Nucleosides, Nucleotides and Nucleic Acids*, **2000**, 19, 253-68 | 1.4 | 6 |
| 57 | Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks. *Antiviral Therapy*, **2000**, 5, 95-104 | 1.6 | 29 |
| 56 | Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. *FASEB Journal*, **1999**, 13, 1511-7 | 0.9 | 62 |
| 55 | A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2′,3′-dideoxy-3′-thiacytidine. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 2077-80 | 5.9 | 11 |
| 54 | Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. *AIDS Research and Human Retroviruses*, **1999**, 15, 1625-30 | 1.6 | 20 |
| 53 | Cell-based and animal models for hepatitis B and C viruses. *Antiviral Chemistry and Chemotherapy*, **1999**, 10, 99-114 | 3.5 | 32 |

| | | | |
|---|---|---|---|
| 52 | Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 2759-66 | 3.4 | 11 |
| 51 | Nucleic acids and nucleosides containing carboranes. *Journal of Organometallic Chemistry*, **1999**, 581, 156-169 | 2.3 | 75 |
| 50 | New classes of fluorinated L-nucleosides; synthesis and antiviral activity. *Nucleosides & Nucleotides*, **1999**, 18, 537-40 | | 21 |
| 49 | Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. *Journal of Medicinal Chemistry*, **1999**, 42, 859-67 | 8.3 | 48 |
| 48 | Synthesis and anti-HIV and anti-HBV activities of 2′-fluoro-2′,3′-unsaturated L-nucleosides. *Journal of Medicinal Chemistry*, **1999**, 42, 1320-8 | 8.3 | 68 |
| 47 | From d-to l-nucleoside analogs as antiviral agents. *Advances in Antiviral Drug Design*, **1999**, 1-68 | | 19 |
| 46 | Pharmacokinetics of the antiviral agent beta-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine in rhesus monkeys. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 381-4 | 5.9 | 13 |
| 45 | Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy. *Antiviral Therapy*, **1999**, 4, 21-28 | 1.6 | 17 |
| 44 | Synthesis and biological properties of the four optical isomers of 5-o-carboranyl-2′,3′-didehydro-2′,3′-dideoxyuridine. *Nucleosides & Nucleotides*, **1998**, 17, 711-27 | | 8 |
| 43 | Pharmacodynamics of (-)-beta-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 2804-9 | 5.9 | 19 |
| 42 | Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir. *Nucleosides & Nucleotides*, **1997**, 16, 2079-2092 | | 12 |
| 41 | A General Synthetic Method of 5-Carboranyluracil Nucleosides with Potential Antiviral Activity and use in Neutron Capture Therapy. *Nucleosides & Nucleotides*, **1997**, 16, 2133-2150 | | 9 |
| 40 | Structure-activity relationships of 2′-deoxy-2′,2′-difluoro-L-erythro-pentofuranosyl nucleosides. *Journal of Medicinal Chemistry*, **1997**, 40, 3635-44 | 8.3 | 46 |
| 39 | Comparison of Physicochemical and Biological Properties of (o-Carboran-1-YL)methylphosphonate and Methylphosphonate Oligonucleotides. *Nucleosides & Nucleotides*, **1997**, 16, 1503-1505 | | 8 |
| 38 | Synthesis of Six-Membered Nucleoside Analogs. Part 1: Pyrimidine Nucleosides Based on the 1,3-Dioxane Ring System. *Nucleosides & Nucleotides*, **1997**, 16, 403-416 | | 6 |
| 37 | Biotransformation and pharmacokinetics of prodrug 9-(beta-D-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(beta-D-1,3-dioxolan-4-yl)guanine in mice. *Antiviral Research*, **1997**, 35, 187-93 | 10.8 | 9 |
| 36 | Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. *Journal of Medicinal Chemistry*, **1996**, 39, 5202-7 | 8.3 | 32 |
| 35 | Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. *Biochemical Pharmacology*, **1996**, 52, 1577-84 | 6 | 50 |

| | | | |
|---|---|---|---|
| 34 | Cloning and expression of sporozoite and oocyst Cryptosporidium parvum recombinant proteins. *Journal of Eukaryotic Microbiology*, **1996**, 43, 83S | 3.6 | 2 |
| 33 | In vitro evaluation of anticryptosporidial agents using MDCK cell culture and chemiluminescence immunoassay. *Journal of Eukaryotic Microbiology*, **1996**, 43, 87S | 3.6 | 8 |
| 32 | A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. *FEMS Microbiology Letters*, **1996**, 136, 251-6 | 2.9 | 27 |
| 31 | In vitro expression of mRNA coding for a Cryptosporidium parvum oocyst wall protein. *Journal of Eukaryotic Microbiology*, **1996**, 43, 84S-85S | 3.6 | 4 |
| 30 | Anti-human immunodeficiency virus type-1 (HIV-1) and anti-hepatitis B virus (HBV) activities of (2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)nucleosides. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 877-880 | 2.9 | 15 |
| 29 | Boron Containing Pyrimidines, Nucleosides, and Oligonucleotides for Neutron Capture Therapy. *Nucleosides & Nucleotides*, **1994**, 13, 849-880 | | 52 |
| 28 | Pharmacokinetics of 5-carboranyl-2′-deoxyuridine in rats. *Journal of Pharmaceutical Sciences*, **1994**, 83, 1697-9 | 3.9 | 11 |
| 27 | Cellular pharmacology and biological activity of 5-carboranyl-2′-deoxyuridine. *International Journal of Radiation Oncology Biology Physics*, **1994**, 28, 1113-20 | 4 | 44 |
| 26 | Carboranyl Oligonucleotides for Antisense Technology and Boron Neutron Capture Therapy of Cancers. *ACS Symposium Series*, **1994**, 169-182 | 0.4 | 11 |
| 25 | Multiple drug effect analysis with confidence interval. *Antiviral Research*, **1994**, 25, 1-11 | 10.8 | 70 |
| 24 | Carboranyl Oligonucleotides. 2. Synthesis and Physicochemical Properties of Dodecathymidylate Containing 5-(o-Carboran-1-yl)-2′-deoxyuridine. *Journal of the American Chemical Society*, **1994**, 116, 7494-7501 | 16.4 | 43 |
| 23 | Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil. *Journal of Medicinal Chemistry*, **1994**, 37, 2583-8 | 8.3 | 16 |
| 22 | L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. *Journal of Medicinal Chemistry*, **1993**, 36, 519-28 | 8.3 | 86 |
| 21 | Derivatives of 4-amino-3,6-disulfonato-1,8-naphthalimide inhibit reverse transcriptase and suppress human and feline immunodeficiency virus expression in cultured cells. *Journal of Cellular Biochemistry*, **1993**, 51, 446-57 | 4.7 | 25 |
| 20 | A Short Synthesis of 2?,3?-Didehydro-3?-deoxythymidine. *Nucleosides & Nucleotides*, **1993**, 12, 149-155 | | 12 |
| 19 | Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. *FASEB Journal*, **1993**, 7, 1070-80 | 0.9 | 13 |
| 18 | Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides. *Bioorganic and Medicinal Chemistry Letters*, **1993**, 3, 693-696 | 2.9 | 12 |
| 17 | The synthesis and anti-hiv activity of pyrimidine dioxolanyl nucleosides. *Bioorganic and Medicinal Chemistry Letters*, **1993**, 3, 169-174 | 2.9 | 22 |

| | | | |
|---|---|---|---|
| 16 | 1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. *Journal of Medicinal Chemistry*, **1993**, 36, 30-7 | 8.3 | 84 |
| 15 | Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2-deoxycytidine kinase. *Biochemical Pharmacology*, **1993**, 45, 1540-3 | 6 | 87 |
| 14 | Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2,3-dideoxy-5-fluoro-3-thiacytidine (FTC) and related compounds. *Journal of Organic Chemistry*, **1992**, 57, 5563-5565 | 4.2 | 83 |
| 13 | Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity. *Journal of Medicinal Chemistry*, **1992**, 35, 1987-95 | 8.3 | 104 |
| 12 | Synthesis of enantiomerically pure (2R,5S)-(-)-1-(2-hydroxymethyloxathiolan-5-yl)cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). *Journal of Organic Chemistry*, **1992**, 57, 2217-2219 | 4.2 | 192 |
| 11 | Asymmetric synthesis of enantiomerically pure (1?R,4?R)-dioxolane-thymine and its anti-HIV activity.. *Tetrahedron Letters*, **1991**, 32, 3791-3794 | 2 | 52 |
| 10 | In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs. *Journal of the American Chemical Society*, **1991**, 113, 9377-9379 | 16.4 | 120 |
| 9 | Comparative pharmacokinetics and interspecies scaling of 3-azido-3-deoxythymidine (AZT) in several mammalian species. *Journal of Pharmacobio-dynamics*, **1990**, 13, 206-11 | | 35 |
| 8 | 3-Azido-2,3-dideoxyuridine (AzddU): comparative pharmacokinetics with 3-azido-3-deoxythymidine (AZT) in monkeys. *AIDS Research and Human Retroviruses*, **1990**, 6, 219-28 | 1.6 | 38 |
| 7 | Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships. *Journal of Medicinal Chemistry*, **1986**, 29, 151-4 | 8.3 | 37 |
| 6 | Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents. *Journal of Medicinal Chemistry*, **1985**, 28, 741-8 | 8.3 | 48 |
| 5 | Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. *Antimicrobial Agents and Chemotherapy*, **1981**, 19, 672-4 | 5.9 | 53 |
| 4 | Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2-deoxyuridine; 5-iodo-2-deoxycytidine; 5-iodo-5-amino-2,5-dideoxyuridine **1979**, 7, 1-34 | | 31 |
| 3 | Antiviral and antineoplastic activities of pyrimidine arabinosyl nucleosides and their 5-amino derivatives. *Journal of Medicinal Chemistry*, **1979**, 22, 1273-7 | 8.3 | 25 |
| 2 | Mechanism of action of HBV capsid assembly modulators predicted from binding to early assembly intermediates | | 2 |
| 1 | Disproportionate presence of adenosine in mitochondrial and chloroplast DNA ofChlamydomonas reinhardtii | | 1 |